4A. H. Talal,J. LaFleur,R. Hoop,P. Pandya,P. Martin,I. Jacobson,J. Han,E. J. Korner.Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV ‐infected, evaluated patients[J]. Aliment Pharmacol Ther . 2013 (4)
5European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology . 2011
6European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology . 2015
7Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England Journal of Medicine . 2014
8European Medicines Agency-Science Medicine Healts.Harvoni summary of product characteristics. http//www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/003850/WC500177995.pdf . 2015
9Food and Drug Administration,U.S.National Library of Medicine,National Center for Biotechnology Information.Compound Summary for CID 86291595 Viekira Pak. http//pubchem.ncbi.nlm.nih.gov/compound/86291595 . 2015
10European Medicines Agency-Science Medicine Healts.Olysio summary of product characteristics. http//www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002777/WC500167867.pdf . 2015
